ReviewHuman vaccines & immunotherapeutics2019
Classical and novel strategies to develop a
Review in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 73 citations in OpenAlex.
- Exploring the multidimensional factors associated with the incidence of bacillary dysentery in China based on a panel data model.Frontiers in public health · 2026Article
- Development of themSphere · 2023Article
- Toward aInternational journal of molecular sciences · 2023Review
- Immunologically effective biomaterials-enhanced vaccines against infection of pathogenic microorganisms.Biosafety and health · 2023Review
- The Diversity ofMicroorganisms · 2023Review
- Facile synthesis of multi-faceted, biomimetic and cross-protective nanoparticle-based vaccines for drug-resistant Shigella: a flexible platform technology.Journal of nanobiotechnology · 2023Article
- Comparison ofFrontiers in molecular biosciences · 2023Article
- Computational Design of a Chimeric Vaccine againstVaccines · 2022Article
- Semisynthetic Glycoconjugate Vaccine Candidates againstJACS Au · 2022Article
- Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022Review
- Recent advances on smart glycoconjugate vaccines in infections and cancer.The FEBS journal · 2022Review
- Vaccination against Bacterial Infections: Challenges, Progress, and New Approaches with a Focus on Intracellular Bacteria.Vaccines · 2022Review
- The First-in-Human Synthetic Glycan-Based Conjugate Vaccine Candidate againstACS central science · 2022Article
- Detoxified O-Specific Polysaccharide (O-SP)-Protein Conjugates: Emerging Approach in theVaccines · 2022Review
- Review
- Review
- Shigella Outer Membrane Vesicles as Promising Targets for Vaccination.International journal of molecular sciences · 2022Review
- Safety and Immunogenicity of aVaccines · 2021Article
- Impact of O-Acetylation onMicroorganisms · 2021Article
- Comparison and Optimization of Quantification Methods forInternational journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.